Skip to main content
SpringerLink
Log in

Glutamate receptor antagonists and neuropathic pain

  • Chapter
Mechanisms and Mediators of Neuropathic Pain

Part of the book series: Progress in Inflammation Research ((PIR))

  • 152 Accesses

Abstract

Glutamate is the quantitatively most important excitatory neurotransmitter in the central nervous system with three main receptor subtypes (metabotropic, nonNMDA and NMDA receptor subtypes). The various glutamate receptor subtypes play an important role in the pathophysiology of numerous central nervous system diseases, including acute excitotoxic neurodegeneration (e.g. cerebral ischaemia, stroke and brain injury), chronic excitotoxic neurodegeneration (e.g. dementia of the Alzheimer type, Parkinsonism and Huntington’s disease), epilepsy and psychiatric disorders (e.g. anxiety, depression and schizophrenia) [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Parsons CG, Danysz W, Quack G (1998) Glutamate in CNS disorders as a target for drug development: An update. Drug News Perspect 11: 523–569

    Article  PubMed  CAS  Google Scholar 

  2. Dubner R (1997) Neural basis of persistent pain: Sensory specialization, sensory modu-lation, and neuronal plasticity. In:TS Jensen, JA Turner, Z Wiesenfeld-Hallin (eds): Proceedings of the 8th World Congress on Pain. Progress in pain research and management, Vol. 8, IASP Press, Seattle, 243–257

    Google Scholar 

  3. Dickenson A (1997) Mechanisms of central hypersensitivity: Excitatory amino acid mechanisms and their control. In: A Dickenson, JM Besson (eds): The pharmacology of pain. Springer Verlag, Berlin, 167–210.

    Chapter  Google Scholar 

  4. Bennett GJ (1994) Neuropathic pain. In: PD Wall, RM Melzack (eds): Textbook of pain. Churchill Livingstone, Edinburgh, 201–224

    Google Scholar 

  5. Anis NA, Berry SC, Burton NR, Lodge D (1983) The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by Nmethyl-aspartate. Br J Pharmacology 79: 565–575

    Article  CAS  Google Scholar 

  6. Eide PK, Stubhaug A, Breivik H, Oye I (1997) Reply to ST Meller: Ketamine: Relief from chronic pain through actions at the NMDA receptor. Pain 72: 289–291

    Article  PubMed  CAS  Google Scholar 

  7. Choi DW, Peter S, Viseskul V (1987) Dextrorphan and levorphanol selectively block Nmethyl-D-aspartate receptor-mediated neurotoxicity on cortical neurons. J Pharmacol Exp Ther 242: 713–720.

    CAS  Google Scholar 

  8. Parsons CG, Gruner R, Rozental J, Millar J, Lodge D (1993) Patch clamp studies on the kinetics and selectivity of N-Methyl-D-Aspartate receptor antagonism by memantine (1amino-3,5-dimethyladamantan). Neuropharmacology 32: 1337–1350

    Article  PubMed  CAS  Google Scholar 

  9. Yaksh TL (1989) Behavioral and autonomic correlates of the tactile evoked allodynia produced by spinal glycine inhibition: Effects of modulatory receptor systems and excitatory amino acid antagonists. Pain 37: 111–123

    Article  PubMed  CAS  Google Scholar 

  10. Davar G, Hama A, Deykin A, Vos B, Maciewics R (1991) MK-801 blocks the development of thermal hyperalgesia in a rat model of experimental painful neuropathy. Brain Res 553: 327–330

    Article  PubMed  CAS  Google Scholar 

  11. Mao J, Price DD, Mayer DJ, Lu J, Hayes RL (1992) Intrathecal MK-801 and local nerve anesthesia synergistically reduce nociceptive behaviors in rats with experimental peripheral mononeuropathy. Brain Res 576: 254–262

    Article  PubMed  CAS  Google Scholar 

  12. Mao J, Price DD, Hayes RL, Lu J, Mayer DJ, Frenk H (1993) Intrathecal treatment with dextrorphan or ketamine potently reduces pain-related behaviors in a rat model of peripheral mononeuropathy. Brain Res 605: 164–168

    Article  PubMed  CAS  Google Scholar 

  13. Tal M, Bennett GJ (1993) Dextrorphan relieves neuropathic heat-evoked hyperalgesia in the rat. Neurosci Lett 151: 107–110

    Article  PubMed  CAS  Google Scholar 

  14. Yamamoto T, Yaksh TL (1992) Spinal pharmacology of thermal hyperesthesia induced by constriction injury of sciatic nerve. Excitatory amino acid antagonists. Pain 49: 121–128

    Article  PubMed  CAS  Google Scholar 

  15. Smith GD, Wiseman J, Harrison SM, Elliott PJ, Birch PJ (1994) Pretreatment with MK-801, a non-competitive NMDA antagonist, prevents development of mechanical hyperalgesia in a rat model of chronic neuropathy, but not in a model of chronic inflammation. Neurosci Lett 165: 79–83

    Article  PubMed  CAS  Google Scholar 

  16. Qian J, Brown SD, Carlton SM (1996) Systemic ketamine attenuates nociceptive behaviors in a rat model of peripheral neuropathy. Brain Res 715: 51–62

    Article  PubMed  CAS  Google Scholar 

  17. Chaplan SR, Malmberg AB, Yaksh TL (19997) Efficacy of spinal NMDA receptor antagonism in formalin hyperalgesia and nerve injury evoked allodynia in the rat. J Pharmacol Exp Ther 280: 829–838

    Google Scholar 

  18. Xu X-J, Hao J-X, Seiger A, Wiesenfeld-Hallin Z (1993) Systemic excitatory amino acid receptor antagonists of the a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor and of the N-methyl-D-aspartate (NMDA) receptor relieve mechanical hypersenitivity after transient spinal cord ischemia in rats. J Pharmacol Exp Ther 267: 140–144

    PubMed  CAS  Google Scholar 

  19. Hao J-X, Xu X-J (1996) Treatment of a chronic allodynia-like response in spinally injured rats: Effects of systemically administered excitatory amino acid receptor antagonists. Pain 66: 279–285

    Article  PubMed  CAS  Google Scholar 

  20. Christensen D, Gautron M, Guilbaud G, Kayser V (1999) Combined systemic administration of the glycine/NMDA receptor antagonist, (+)-HA966 and morphine attenuates pain-related behaviour in a rat model of trigeminal neuropathic pain. Pain 83: 433–440.

    Article  PubMed  CAS  Google Scholar 

  21. Yamamoto T, Yaksh TL (1992) Studies on the spinal interaction of morphine and the NMDA antagonist MK-801 on the hyperesthesia observed in a rat model of sciatic mononeuropathy. Neurosci Lett 135: 67–70

    Article  PubMed  CAS  Google Scholar 

  22. Backonja M, Arndt G, Gombar KA, Check B, Zimmermann M (1994) Response of chronic neuropathic pain syndromes to ketamine: A preliminary study. Pain 56: 51–57

    Article  PubMed  CAS  Google Scholar 

  23. Eide PK, Stubhaug A, Oye I, Breivik H (1995) Continuous subcutaneous administration of the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia. Pain 61: 221–228

    Article  PubMed  CAS  Google Scholar 

  24. Eide PK, Stubhaug A (1997) Relief of glossopharyngeal neuralgia by ketamine-induced N-methyl-aspartate receptor blockade. Neurosurgery 41: 505–508

    Article  PubMed  CAS  Google Scholar 

  25. Hoffmann V, Coppejans H, Vercauteren M, Adriaensen H (1994) Successful treatment of postherpetic neuralgia with oral ketamine. Clin J Pain 10: 240–242

    Article  PubMed  CAS  Google Scholar 

  26. Klepstad P, Borchgrevink PC (1997) Four years’ treatment with ketamine and a trial of dextrometorphan in a patient with severe post-herpetic neuralgia. Acta Anaesthesiol Scand 41: 422–426

    Article  PubMed  CAS  Google Scholar 

  27. Mathisen LC, Skjelbred P, Skoglund LA, Oye I (1995) Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain. Pain 61: 215–220

    Article  PubMed  CAS  Google Scholar 

  28. Nikolajsen L, Hansen PO, Jensen TS (1997) Oral ketamine therapy in the treatment of postamputation stump pain. Acta Anaesthesiol Scand 41: 427–429

    Article  PubMed  CAS  Google Scholar 

  29. Stannard CF, Porter GE (1993) Ketamine hydrochloride in the treatment of phantom limb pain. Pain 54: 227–230

    Article  PubMed  CAS  Google Scholar 

  30. Kristensen JD, Svensson B, Gordh T (1992) The NMDA-receptor antagonist CPP abolishes neurogenic “wind-up pain” after intrathecal administration in humans. Pain 51: 249–253

    Article  PubMed  CAS  Google Scholar 

  31. Takahashi H, Miyazaki M, Nanbu T, Yanagida H, Morita S (1998) The NMDA-receptor antagonist ketamine abolishes neuropathic pain after epidural administration in a clinical case. Pain 75: 391–394

    Article  PubMed  CAS  Google Scholar 

  32. Eisenberg E, Pud D (1998) Can patients with chronic neuropathic pain be cured by acute administration of the NMDA receptor antagonist amantadine? Pain 74: 337–339

    Article  PubMed  CAS  Google Scholar 

  33. Rabben T, Skjelbred P, Oye I (1999) Prolonged analgesic effect of ketamine, an N-methyl-D-aspartate receptor inhibitor, in patients with chronic pain. J Pharmacol Exp Ther 289: 1060–1066

    PubMed  CAS  Google Scholar 

  34. Eide PK, Jorum E, Stubhaug A, Bremnes J, Breivik H (1994) Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine. A double-blind, cross-over comparison with morphine and placebo. Pain 58: 347-354

    Article  PubMed  CAS  Google Scholar 

  35. Felsby S, Nielsen J, Arendt-Nielsen L, Jensen TS (1995) NMDA receptor blockade in chronic neuropathic pain: A comparison of ketamine and magnesium chloride. Pain 64: 283–291

    Article  Google Scholar 

  36. Max MB, Byas-Smith MG, Gracely RH, Bennett GJ (1995) Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: A double-blind comparison to alfentanil and placebo. Clin Neuropharmacol 18: 360–368

    Article  PubMed  CAS  Google Scholar 

  37. Nikolajsen L, Hansen CL, Nielsen J, Keller J, Arendt-Nielsen L, Jensen TS (1996) The effect of ketamine on phantom pain: A central neuropathic disorder maintained by peripheral input. Pain 67: 69–77

    Article  PubMed  CAS  Google Scholar 

  38. Eide PK, Stubhaug A, Stenehjem AE (1995) Central dysesthesia pain after traumatic spinal cord injury is dependent on N-methyl-D-aspartate receptor activation. Neurosurgery 37: 1080–1087.

    Article  PubMed  CAS  Google Scholar 

  39. Pud D, Eisenberg E, Spitzer A, Adler R, Fried G, Yarnitsky D (1998) The NMDA receptor antagonist amantadine reduces surgical neuroapthic pain in cancer patients: A double blind, randomized, placebo controlled trial. Pain 75: 349–354

    Article  PubMed  CAS  Google Scholar 

  40. McQuay HJ, Carroll D, Jadad AR, Glynn CJ, Jack T, Moore RA, Wiffen PJ (1994) Dextromethorphan for the treatment of neuropathic pain: A double-blind randomised controlled crossover trial with integral n-of-1 design. Pain 59: 127–133

    Article  PubMed  CAS  Google Scholar 

  41. Nelson KA, Park KM, Robinovitz E, Tsigos C, Max MB (1997) High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 48: 1212–1218

    Article  PubMed  CAS  Google Scholar 

  42. Eisenberg E, Kleiser A, Dortort A, Haim T, Yarnitsky D (1998) The NMDA (N-methylD-aspartate) receptor antagonist memantine in the treatment of postherpetic neuralgia: A double-blind, placebo-controlled study. Eur J Pain 2: 321–327

    Article  CAS  Google Scholar 

  43. Stubhaug A, Eide PK, Oye I, Breivik H (2002) The combination of oral morphine and ketamine improves pain relief in postherpetic neuralgia compared with morphine or ketamine alone. A randomised, double-blind, placebo-controlled crossover comparison. Pain; in press

    Google Scholar 

  44. Persson J, Axelsson G, Hallin RG, Gustafsson LL (1995) Beneficial effects of ketamine in a chronic pain state with allodynia, possibly due to central sensitization. Pain 60: 217–222

    Article  PubMed  CAS  Google Scholar 

  45. Olney JW, Farber NB (1995) NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 13: 335–345

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, The National Hospital, University of Oslo, Sognvannsveien 20, N-0027, Oslo, Norway

    Per Kristian Eide

Authors
  1. Per Kristian Eide
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. NeurogesX, Inc., 969C Industrial Road, San Carlos, CA, 94070, USA

    Annika B. Malmberg PhD

  2. RW Johnson Pharmaceutical Institute, 3210 Merryfield Row, San Diego, CA, 92121, USA

    Sandra R. Chaplan MD

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Basel AG

About this chapter

Cite this chapter

Eide, P.K. (2002). Glutamate receptor antagonists and neuropathic pain. In: Malmberg, A.B., Chaplan, S.R. (eds) Mechanisms and Mediators of Neuropathic Pain. Progress in Inflammation Research. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8129-6_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8129-6_11

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9448-7

  • Online ISBN: 978-3-0348-8129-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation